ClinicoEconomics and Outcomes Research最新文献

{"title":"Cost Minimization and Cost Comparison of the Use of Conventional Double Lumen Tube versus Single-Use VivaSight-Double Lumen Tube in Thoracic Surgery: The Pascale Institute Experience.","authors":"Maurizio Marchesini, Michela D'Antò, Rosanna Accardo, Marika Aprea, Giuseppe D'Agostino, Maria Romano, Vittorio Santoriello, Gilda Pasta, Francesca Bifulco, Arturo Cuomo","doi":"10.2147/CEOR.S578308","DOIUrl":"https://doi.org/10.2147/CEOR.S578308","url":null,"abstract":"<p><strong>Purpose: </strong>One lung ventilation (OLV) is essential in thoracic surgery to isolate and ventilate a single lung, ensuring optimal surgical exposure and patient safety. Precise placement of a double lumen tube (DLT) is critical and conventionally confirmed via reusable bronchoscopy.</p><p><strong>Patients and methods: </strong>We evaluated the economic and organisational impact of introducing VivaSightDLT-an endobronchial tube with an integrated camera-at Fondazione G. Pascale (Naples). Data from 50 patients were reviewed to compare device efficacy and positioning accuracy. Cost data from the Institute's management control informed a cost minimization analysis (CMA) and cost comparison analysis (CCA), projecting financial outcomes over 1, 3, and 5 years, based on an annual thoracic surgery volume of 400 cases (328 eligible for VivaSightDLT).</p><p><strong>Results: </strong>Although the per unit cost of VivaSightDLT exceeds that of the conventional DLT, mean savings per procedure were €86.36. When additional intraoperative bronchoscopic checks were required, savings increased to €193.89 per case. Net savings of €16,728.54 at 1 year, €50,185.62 at 3 years, and €83,642.70 at 5 years (15% reduction in direct variable costs) were projected. Full replacement of conventional DLTs would yield a 41% reduction in direct variable costs (€33,457.08, €100,371.25, and €167,285.41 over 1, 3, and 5 years, respectively). VivaSightDLT also reduced operative times by 14-25 minutes (19.5 min IC95%: 14-25), enhancing operating room turnover.</p><p><strong>Conclusion: </strong>The integration of VivaSight DLT at the Istituto Nazionale Tumori, Fondazione G. Pascale, demonstrates superior cost-effectiveness and procedural organisational efficiency compared to conventional DLTs. By eliminating routine reusable bronchoscopy and reducing procedure duration, VivaSight DLT represents an optimal strategy for OLV in thoracic surgery.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"578308"},"PeriodicalIF":2.2,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13055866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Progression-Free Survival and Healthcare Resource Utilization Associated with Daratumumab Use in Transplant-Ineligible Multiple Myeloma Patients in Italy.","authors":"Valentina Perrone, Gregorio Barilà, Luca Franceschini, Giuseppe Mele, Stefania Mazzoni, Maria Cappuccilli, Margherita Andretta, Marcello Bacca, Fausto Bartolini, Antonietta Barbieri, Alessandra Blasi, Alessandro Chinellato, Stefania Dell'Orco, Fulvio Ferrante, Renato Lombardi, Daniela Mancini, Romina Pagliaro, Arrigo Paciello, Maurizio Pastorello, Cataldo Procacci, Daniela Ricciardulli, Loredana Ubertazzo, Paola Valpondi, Alberto Zucchi, Luca Degli Esposti","doi":"10.2147/CEOR.S585246","DOIUrl":"https://doi.org/10.2147/CEOR.S585246","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated real-world clinical and economic outcomes associated with daratumumab-based regimens in patients with multiple myeloma (MM) ineligible for autologous stem cell transplantation (ASCT) in Italy. Differences in healthcare resource use according to daratumumab administration route (intravenous vs subcutaneous) were also explored.</p><p><strong>Methods: </strong>A retrospective observational analysis was conducted using administrative healthcare databases from Italian Local Health Units covering ~12 million individuals (2018-2023). Patients with MM receiving daratumumab in first-line (1L) or second-line (2L) therapy were included. Real-world progression-free survival (rwPFS), defined as time to treatment switch or death, was used as a proxy endpoint for disease progression, and healthcare resource utilization were compared between treatment regimens. Propensity score weighting was applied to to improve comparability between treatment groups. Direct healthcare costs captured in administrative databases were analyzed from the perspective of the Italian National Health System.</p><p><strong>Results: </strong>Among 790 non-ASCT MM patients, 344 received 1L DaraRd and 413 received 2L DaraRd. In the 1L setting, median rwPFS was not reached for DaraRd and was 25.7 months for Rd (p=0.011). In 2L, median rwPFS was 42.9 months for DaraRd versus 19.1 months for Rd (p <0.001). In 1L, DaraRd was associated with lower hospitalization costs compared with Rd for both all-cause (€4324 vs €7971) and MM-related (€2862 vs €6693) admissions. In 2L, differences in hospitalization costs were smaller and not statistically significant.</p><p><strong>Conclusion: </strong>In this real-world analysis, daratumumab-based regimens were associated with longer rwPFS compared with Rd among transplant-ineligible MM patients, in both 1L and 2 L settings. In 1L treatment, these outcomes were accompanied by lower hospitalization costs. Given the retrospective design and the use of administrative healthcare data, these findings should be interpreted with caution, but they contribute to the growing body of real-world evidence on treatment outcomes and resource utilization in routine clinical practice.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"585246"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Utilization and Costs After Appropriate or Inappropriate Implantable Defibrillator Shocks: A Retrospective Real-World Data Study in Japan.","authors":"Takashi Noda, Tomoko Matsumoto, Yuji Tanaka, Tadahiro Goto","doi":"10.2147/CEOR.S577970","DOIUrl":"https://doi.org/10.2147/CEOR.S577970","url":null,"abstract":"<p><strong>Background: </strong>Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy with defibrillators (CRT-Ds) effectively prevent sudden cardiac death. However, there is a lack of detailed data on healthcare utilization and healthcare cost following ICD/CRT-D shock events in Japan. This study aimed to examine real-world data (RWD) stored in an emergency department system to clarify healthcare utilization and healthcare costs associated with ICD/CRT-D shocks in Japan.</p><p><strong>Methods and results: </strong>This retrospective study analyzed RWD from four tertiary hospitals between January 2022 to June 2024. Among 1,807 ICD/CRT-D implanted adult patients, 84 patients (4.6%) who visited the hospital at least once following an ICD/CRT-D shock event were identified. Of these, a total of 146 ICD/CRT-D shock events were observed, with 33 patients (39.3%) experiencing multiple episodes. Of these, 122 (83.6%) were appropriate and 24 (16.4%) were inappropriate. Hospitalization was required in 55 (37.7%) cases. Appropriate shocks were associated with longer hospital stays (24.6 ± 29.3 vs. 12.5 ± 4.2 days) and higher costs (1,123,531 ± 2,195,483 JPY vs. 67,091 ± 131,282 JPY) than inappropriate shocks.</p><p><strong>Conclusion: </strong>In this multicenter retrospective study using real-world data in Japan, we investigated the healthcare utilization and costs associated with ICD/CRT-D shock events. Our findings provide valuable insight into post-shock care in daily practice and highlight the need for optimized management strategies to improve care delivery and resource use in the Japanese clinical setting.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"577970"},"PeriodicalIF":2.2,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13050171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Drug Cost-Exemption Policy on Treatment Outcomes in Multidrug-Resistant Tuberculosis Patients in Guangxi Zhuang Autonomous Region, China: A Nested Case-Control Study.","authors":"Aimei Liu, Yan Liao, Juexian Ye, Qing Wang, Junli Huang, Yucheng Tang, Lizhen Feng","doi":"10.2147/CEOR.S577874","DOIUrl":"https://doi.org/10.2147/CEOR.S577874","url":null,"abstract":"<p><strong>Background: </strong>The most effective patient support interventions in low- and middle-income countries remain a research gap in World Health Organization consolidated guidelines on tuberculosis. We explored the impact of a partial drug cost-exemption policy (including cycloserine, moxifloxacin, linezolid, and clofazimine) implemented in Guangxi Zhuang Autonomous Region, China, on treatment outcomes among local multidrug-resistant tuberculosis (MDR-TB) patients.</p><p><strong>Methods: </strong>This case-control study enrolled 424 MDR-TB patients receiving anti-TB treatment between 2020 and 2022 in Guangxi Zhuang Autonomous Region. Data on demographics, treatment regimen, drug cost-exemption status, and adverse reactions were extracted from electronic medical records. Multivariable logistic regression analysis was used to identify factors associated with successful treatment outcomes.</p><p><strong>Results: </strong>Among the 424 enrolled MDR-TB patients, 212 (50.0%) had successful treatment outcomes, including 79 cured (18.6%) and 133 treatment completed (31.4%). Unfavorable outcomes were observed in 212 patients (50.0%), comprising 190 lost to follow-up (44.8%), 19 deaths (4.5%), and 3 treatment failures (0.7%). Multivariable analysis revealed that female sex (aOR = 2.99, 95% CI: 1.55-5.78), absence of adverse drug reactions (aOR = 11.58, 95% CI: 3.81-35.18), and receiving drug cost-exemption (aOR = 37.47, 95% CI: 10.97-127.96) were associated with favorable treatment outcomes. Furthermore, receiving an increasing number of exempted drugs was progressively associated with higher treatment success. Compared to one drug exemption, the aOR for successful outcomes was 3.24 (95% CI: 2.16-4.87) for two-drug cost-exemption and 5.13 (95% CI: 2.73-9.65) for three-drug cost-exemption.</p><p><strong>Conclusion: </strong>This nested case-control study demonstrates that implementing drug cost-exemption support policy is associated with significantly improved MDR-TB treatment success rates in resource-limited, high-burden settings in China.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"577874"},"PeriodicalIF":2.2,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13037532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activity-Based Costing of COVID-19 RT-PCR Testing in Public Laboratories in Indonesia: Evidence for Tariff Setting.","authors":"Sabarudin Sabarudin, Mohammed Alfaqeeh, Nurramadhani A Sida, Nita Trinovitasari, Ruslin Ruslin, Dina Abushanab, Wening Wulandari, Miski A Khairinisa, Auliya A Suwantika","doi":"10.2147/CEOR.S596722","DOIUrl":"10.2147/CEOR.S596722","url":null,"abstract":"<p><strong>Background: </strong>Reverse transcriptase-polymerase chain reaction (RT-PCR) testing has been central to Indonesia's COVID-19 response. However, limited empirical evidence exists on the actual cost of RT-PCR testing in public laboratories, raising concerns that regulated tariffs may not accurately reflect resource use, particularly in low- and middle-income settings.</p><p><strong>Purpose: </strong>This study aimed to estimate the unit cost of COVID-19 RT-PCR testing and identify key cost drivers to inform evidence-based tariff setting and support the financial sustainability of public laboratories in Indonesia.</p><p><strong>Methods: </strong>A micro-costing analysis using an Activity-Based Costing (ABC) approach was conducted across eight government-owned laboratories in Southeast Sulawesi, Indonesia. Costs were categorized into direct and indirect components, and the unit cost was calculated by dividing total operational costs by the average number of tests performed per month. One-way sensitivity analyses were performed to assess the influence of major cost components.</p><p><strong>Results: </strong>The adjusted mean unit cost of RT-PCR testing was USD 21.02, based on an average testing volume of 5409 samples per month and total adjusted monthly operating expenditures of USD 100,973.89. Direct costs accounted for 92.58% of total costs, driven primarily by consumables (75.12%) and human resources (13.32%). Extraction kits and RT-PCR reagents were the most influential cost drivers in sensitivity analyses. The estimated unit cost exceeded the government-mandated RT-PCR tariff outside Java and Bali (approximately USD 17-18.5).</p><p><strong>Conclusion: </strong>This study provides empirical evidence on the actual cost of COVID-19 RT-PCR testing in Indonesian public laboratories. The findings highlight a mismatch between regulated tariffs and real service delivery costs, underscoring the need for tariff adjustments that balance affordability for patients with financial sustainability for laboratories. Transparent cost information is essential to support evidence-based pricing policies and strengthen preparedness for future public health emergencies.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"596722"},"PeriodicalIF":2.2,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13006015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147505244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness and Clinical Utility of Pancreatic Cancer Non-Invasive Test in New-Onset Diabetes.","authors":"Adrian Vilalta, Ananya Das, Michael B Wallace","doi":"10.2147/CEOR.S577796","DOIUrl":"https://doi.org/10.2147/CEOR.S577796","url":null,"abstract":"<p><strong>Importance: </strong>Most pancreatic cancer (PC) cases are diagnosed at a late stage, leading to poor prognosis. New-onset diabetes (NOD) increases the risk of PC by 6- to 8-fold within the first 3 years of diagnosis. This study aims to assess the clinical utility and economic benefits of early detection of PC in patients with NOD using a cell-free DNA (cfDNA) epigenomic blood test (Avantect; ClearNote Health, CA).</p><p><strong>Design: </strong>A Markov model compares two primary strategies: no testing and testing higher-risk NOD patients using the cfDNA epigenomic test. Using the enriching new-onset diabetes for pancreatic cancer (END-PAC) criteria ≥3, approximately 20% of the NOD patients were at higher risk for PC. The cfDNA epigenomic test has a sensitivity of 68% and a specificity of 97%.</p><p><strong>Results: </strong>The cfDNA test is robustly cost-effective in NOD high-risk patients, with an Incremental Cost-Effectiveness Ratio (ICER) of $56,564 at a Willingness-to-Pay (WTP) threshold of $100,000; its cost-effectiveness is superior to the standard of care, ie, no testing. In a modeled cohort of 10,000 NOD patients, the no-testing strategy would result in 1% of PC cases, with only 7.1% being eligible for potentially curative surgery. By contrast, cfDNA testing identified 71 cases of PC, with 32.4% of these cases being eligible for surgical resection. Early-stage detection through this approach more than quadruples surgical eligibility and significantly enhances the chances of a cure.</p><p><strong>Conclusions and relevance: </strong>These findings underscore the transformative clinical and economic value of early PC detection in high-risk patients with NOD. Implementing cfDNA testing during the first three years following diabetes onset has the potential to shift the diagnosis paradigm, leading to early interventions and meaningful improvements in expected survival, while remaining cost-effective.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"577796"},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Willingness to Pay and Quality of Life in Acne Patients: A Cross-Sectional Study with a Nomogram for Individualized Prediction.","authors":"Xiangzi Li, Xintao Cen, Ning Ning, Chao Li, Yaqian Zhu, Jiarui Liu, Qian Zhu, Shiyu He, Yang Guan","doi":"10.2147/CEOR.S579111","DOIUrl":"https://doi.org/10.2147/CEOR.S579111","url":null,"abstract":"<p><strong>Purpose: </strong>To examine willingness to pay (WTP) for acne treatment and its associated factors, to assess the relationship between WTP and dermatology-specific quality of life as measured by the Dermatology Life Quality Index (DLQI), and to develop and internally validate a nomogram for predicting high WTP, with the aim of supporting individualized acne management and informed healthcare resource allocation.</p><p><strong>Methods: </strong>Patients with acne completed an electronic questionnaire assessing their WTP for a hypothetical one-time curative treatment, along with demographic, clinical, and DLQI data. High WTP was defined as >4000 CNY. Multivariable logistic regression identified factors associated with high WTP, and restricted cubic spline analysis explored the relationship between WTP and DLQI scores. The dataset was randomly divided into training (70%) and testing (30%) cohorts. LASSO regression was used to identify key predictors of WTP. The variables retained by LASSO were subsequently entered into a multivariate logistic regression prediction model, and the independent predictors were incorporated into a nomogram to estimate the probability of high WTP for each patient.</p><p><strong>Results: </strong>A total of 456 patients were included. Multivariate logistic regression analysis revealed that female sex, aged ≥25 years, monthly income ≥5000 CNY, moderate or severe acne, prior treatment history (medications, chemical peels, or combination therapies), recurrent acne, and annual acne-related expenditure >1000 CNY were significantly associated with high WTP. DLQI showed a linear relationship with WTP (<i>P_overall</i> = 0.04, <i>P</i> _nonlinear = 0.77). Eight independent predictors identified from multivariable analyses were incorporated into the predictive nomogram, which showed good calibration and discrimination (AUC_train = 0.80; AUC_test = 0.77). Decision-curve analysis indicated clinical utility across threshold probabilities between 0.19 and 0.94.</p><p><strong>Conclusion: </strong>Patients' WTP for acne treatment reflects disease burden and quality-of-life impairment. A nomogram developed and validated in this study provides an effective tool for estimating WTP in acne patients and may support clinical decision-making and health-economic assessment.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"579111"},"PeriodicalIF":2.2,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12994399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Healthcare Costs in Heart Failure and Its Clinical Phenotypes During the Implementation of SGLT2 Inhibitors: A Finnish Registry Study.","authors":"Johan Liseth Hansen, Miikka Tarkia, Marija Vasilevska, Patrik Sandin, Eralda Asllanaj, Karlijn Wammes, Johan Mesterton, K E Juhani Airaksinen","doi":"10.2147/CEOR.S576426","DOIUrl":"https://doi.org/10.2147/CEOR.S576426","url":null,"abstract":"<p><strong>Purpose: </strong>Real-world data on healthcare costs associated with SGLT2 inhibitor use during its early adoption remains limited, particularly across heart failure (HF) phenotypes. This study assessed trends in healthcare resource utilization (HCRU) and costs among HF patients, stratified by SGLT2 inhibitor use and left ventricular ejection fraction (LVEF).</p><p><strong>Patients and methods: </strong>Using Finnish specialty care registry data, adults with a first HF diagnosis between January 1, 2016, and June 30, 2022 were identified and categorized by LVEF as reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) LVEF. Annual SGLT2 inhibitor uptake (2016-2022) was assessed. Patients were stratified by SGLT2 inhibitor use within 365 days of HF diagnosis to assess HCRU and costs trends (2016-2021).</p><p><strong>Results: </strong>Among 119,314 patients, 7,626 (6.4%) initiated SGLT2 inhibitors within a year. Among those with LVEF data (n=16,312/119,314 [13.7%]), HFpEF predominated (58%). SGLT2 inhibitor use in HFrEF increased from 14.4% (2020) to 50.1% (2022). Patients receiving SGLT2 inhibitors were younger (70.8 vs 78.6 years), more often male (65.0% vs 47.2%), and had higher prevalence of type 2 diabetes (72.4% vs 28.5%) compared with those without SGLT2 inhibitor use. From 2016 to 2021, inpatient admissions declined modestly across all groups, with consistently shorter stays among patients with SGLT2 inhibitors compared with those not using them (mean: 20.0 vs 26.3 days [2016]; 17.2 vs 21.7 days [2021]). Outpatient visits and drug dispensations were higher in the SGLT2 inhibitor group. Total annual HCRU costs declined over time, remaining lower for SGLT2 inhibitor users (€30,742 vs €34,235 in 2021), driven by reduced inpatient admission costs.</p><p><strong>Conclusion: </strong>SGLT2 inhibitor uptake increased notably following regulatory approvals. Patients who received SGLT2 inhibitors had lower healthcare costs driven by reduced hospitalization costs, suggesting economic benefits of early SGLT2 inhibitor initiation in HF management and supporting further research evaluation of long-term cost-effectiveness.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"576426"},"PeriodicalIF":2.2,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147475855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study.","authors":"Satoshi Yoshihara, Aster Meche, Patrick Hlavacek, Sarasa M A Johnson, Ann-Sophie Demers, Guido Nador, Shohei Ikoma, Chandra Prakash Yadav, Carla A L Assaf, Marco DiBonaventura, Yong Chen","doi":"10.2147/CEOR.S581258","DOIUrl":"https://doi.org/10.2147/CEOR.S581258","url":null,"abstract":"<p><strong>Introduction: </strong>Elranatamab, a B-cell maturation antigen-CD3 bispecific antibody, was approved in Japan in March 2024 for the treatment of relapsed or refractory multiple myeloma (MM). However, real-world (RW) data on its use remain limited. This retrospective study evaluated patient characteristics and elranatamab treatment patterns in patients with MM in Japan using the Medical Data Vision (MDV) database.</p><p><strong>Methods: </strong>This EVEREST study used de-identified claims data from the MDV database for adult patients with MM who initiated treatment with elranatamab between March 26, 2024, and March 31, 2025. Follow-up was divided, based on expected dosing schedules, into a step-up dosing (SUD) period, a weekly (QW) maintenance period (MP1), an every 2 weeks (Q2W) maintenance period (MP2), and an overall follow-up period. Treatment patterns were reported descriptively. Estimated annual vial usage was extrapolated.</p><p><strong>Results: </strong>Patients (N=253) with a median age of 74 years (range 41-93 years) and median treatment duration of 60.0 days (interquartile range [IQR], 26.0-136.0) were included. The mean (median [IQR]) time between elranatamab administrations across dosing periods were SUD 4.0 days (4.0 [3-4]), MP1 9.8 days (7.0 [7-9]), and MP2 13.0 days (14.0 [7-14]), indicating less frequent dosing than recommended in MP1, and comparable dosing in MP2. Nearly all administrations were in inpatient settings during SUD, and most were in outpatient settings during maintenance periods. Despite variable dosing during the maintenance periods, annual elranatamab usage was lower than the approved label recommendations for Japan (34.4 vs 39.0 vials per year).</p><p><strong>Conclusion: </strong>Early RW data on elranatamab administration and vial usage in patients with MM in Japan suggest that dosing is generally aligned with label expectations, with variable dosing during QW and Q2W maintenance for some patients. Projected vial usage in this RW setting was lower than the expected usage per label.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"581258"},"PeriodicalIF":2.2,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Early Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients with Early Breast Cancer.","authors":"Yanting Ouyang, Yiying Cai, Eileen Yi Ling Poon, Sherilyn Zi Hui Liew, Nicholas Graves","doi":"10.2147/CEOR.S574046","DOIUrl":"https://doi.org/10.2147/CEOR.S574046","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced alopecia is a common side effect with psychological impacts that affect quality of life. Up to 14% of patients may decline chemotherapy due to concerns over hair loss. While existing scalp cooling therapies can reduce alopecia, constraints including space, staffing, and extended chair time limit their use in health services. Hence, a novel scalp cooling cap (\"Product X\") was developed to address this gap. Product X is cordless and portable and does not require patients to remain in treatment chairs post-chemotherapy. This early-stage cost-effectiveness analysis addresses the potential economic value of adopting Product X versus current practice (no scalp cooling).</p><p><strong>Methods: </strong>We developed a decision tree and a lifetime Markov model to estimate change to total costs and health benefits for female patients with early breast cancer, from a health system perspective in a Singapore tertiary cancer care setting. The model incorporated costs related to scalp cooling equipment and administration, chemotherapy, and treatment for cancer recurrence. Assumptions regarding Product X's efficacy and its potential impact on chemotherapy compliance were tested in nine scenario analyses (efficacy: 50%, 75%, 100%; compliance improvement: 0, 1%, 5%). Probabilistic scenario analysis was conducted using Monte Carlo simulation with 1000 iterations from appropriate parameter distributions.</p><p><strong>Results: </strong>In the base case (1% improvement in compliance and 100% efficacy), Product X yielded an incremental cost of S$265 per patient (95% UI: S$251-S$281) and incremental quality-adjusted life years (QALY) of 0.0717 (95% UI: 0.0705-0.0729). At a willingness-to-pay of S$45,000 per QALY, incremental net monetary benefits (INMB) was S$2961 (95% UI: S$2906-S$3015), with >99.9% probability of cost-effectiveness. Across all scenarios, INMB ranged from S$1158 to S$3330.</p><p><strong>Conclusion: </strong>Scenario and probabilistic analyses suggest that Product X is a cost-effective solution for chemotherapy-induced alopecia, supporting its adoption from a health system perspective.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"574046"},"PeriodicalIF":2.2,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12983087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147468582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}